Subject(s)
Chordae Tendineae/diagnostic imaging , Foreign-Body Migration/diagnostic imaging , Portasystemic Shunt, Transjugular Intrahepatic/adverse effects , Stents/adverse effects , Tricuspid Valve/diagnostic imaging , Contrast Media , Fluoroscopy , Humans , Middle Aged , Prosthesis Failure , Tomography, X-Ray Computed , Ultrasonography, Doppler, ColorSubject(s)
Aneurysm/surgery , Portal Vein , Portasystemic Shunt, Transjugular Intrahepatic , Contrast Media , Esophageal and Gastric Varices/complications , Esophageal and Gastric Varices/diagnostic imaging , Hemorrhage/prevention & control , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/diagnostic imaging , Liver Cirrhosis/virology , Male , Middle Aged , Tomography, X-Ray ComputedABSTRACT
BACKGROUND AND AIMS: The restenosis following percutaneous transluminal balloon angioplasty (PTBA) is high for Budd-Chiari syndrome (BCS) patients with hepatic venous obstruction (HVO). We aim to evaluate the safety and long-term outcome of PTBA with a large balloon catheter in a large series of patients with HVO. METHODS: Between January 2005 and December 2013, 93 consecutive BCS patients with HVO were referred for PTBA and subsequently underwent color Doppler ultrasonography or angiography follow-up. Data were retrospectively collected, and follow-up observations were performed at 1-, 2-, 2- to 5-, and 5- to 8-years postoperatively. RESULTS: Percutaneous transluminal balloon angioplasty was technically successful in all patients. Ninety-one patients (97.85%) were treated with PTBA and two with PTBA and stent. Major procedure-related complications occurred in six of the 93 patients (6.45%). The cumulative 1-, 2-, 2- to 5-, and 5- to 8-year primary patency rates were 97.5%, 92.9%, 90%, and 86.5%, respectively. Cumulative 1-, 2-, 2- to 5-, and 5- to 8-year secondary patency rates were 100%, 100%, 98.6%, and 97.3%, respectively. Mean and median primary patency rates were 51.50 ± 3.01 months and 55.0 ± 3.63 months, respectively. Cumulative 1-, 2-, 2- to 5-, and 5- to 8-year survival rates were 98.75%, 98.6%, 100%, and 100%, respectively. Mean and median survival times were 53.10 ± 3.04 months and 55.0 ± 3.64 months, respectively. CONCLUSION: Percutaneous transluminal balloon angioplasty with a large balloon is a safe and effective treatment that could provide excellent rates of long-term patency and survival for the majority of Chinese patients with BCS and HVO.